At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed thyroid cancer of one of the specified subtypes (papillary, follicular, Hürthle cell, insular, medullary, mixed, poorly differentiated, or tall-cell)
- ✓Metastatic and/or locally advanced or locally recurrent disease
- ✓Measurable disease: ≥1 lesion ≥20 mm by conventional techniques or ≥10 mm by spiral CT; bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, lymphangitis, unconfirmed abdominal masses, and cystic lesions not considered measurable
- ✓Not a candidate for radioactive iodine I-131 therapy
- ✕History of allergic reaction to compounds of similar chemical or biologic composition to study drug
- ✕Ongoing or active infection
- ✕Psychiatric illness or social situation that would preclude study compliance
- ✕Other uncontrolled illness
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma
In Brief
A Phase 2 clinical trial evaluating vorinostat for Insular Thyroid Cancer and 6 related conditions. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with metastatic and/or locally advanced or locally recurrent thyroid cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Timeline
Interventions
Given orally